Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease

The intravenous biologics infliximab and vedolizumab are effective long-term therapies for inflammatory bowel disease (IBD). Though highly effective, suboptimal adherence may result in loss of response and adverse sequelae. The extent and outcomes of suboptimal adherence with intravenous biologics,...

Full description

Saved in:
Bibliographic Details
Published in:Research in social and administrative pharmacy 2021-08, Vol.17 (8), p.1420-1425
Main Authors: Haar, Geoffrey S., Vasudevan, Abhinav, Curtain, Colin M., van Langenberg, Daniel R.
Format: Article
Language:English
Subjects:
Adherence
Biologics
Inflammatory bowel disease
Infliximab
Vedolizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The intravenous biologics infliximab and vedolizumab are effective long-term therapies for inflammatory bowel disease (IBD). Though highly effective, suboptimal adherence may result in loss of response and adverse sequelae. The extent and outcomes of suboptimal adherence with intravenous biologics, including in IBD, requires further evaluation. To ascertain adherence to infliximab and vedolizumab infusions, and determine factors associated with poorer adherence within an IBD cohort. A retrospective single-centre cohort study of IBD patients, assessing adherence to infliximab and vedolizumab over 2 years (July 1, 2017 to June 30, 2019) was conducted. Medical and pharmacy dispensing records were used to determine date of infusion. Adherence was assessed using the continuous, multiple interval measure of medication gaps (CMG). Objectively measured disease remission was achieved if one or more of endoscopic remission, faecal calprotectin
ISSN:1551-7411
1934-8150
DOI:10.1016/j.sapharm.2020.10.011